Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNPAT | O15228 | 1/20 | 0.41 |
| ▸ | NMT2 | O60551 | 1/20 | 0.40 |
| ▸ | NMT1 | P30419 | 1/20 | 0.40 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | FURIN | P09958 | 7/20 | 0.39 |
| ▸ | TLR2 | O60603 | 1/20 | 0.38 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.37 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.37 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13402927 | 0.87 | NMT2 (0.45) | GNPATNMT2NMT1SIRT5FURIN | |
| SCHEMBL10169222 | 0.86 | ECE1 (0.43) | GNPAT | |
| SCHEMBL13402926 | 0.85 | NMT2 (0.45) | GNPATNMT2NMT1SIRT5FURIN | |
| SCHEMBL13402932 | 0.84 | NMT2 (0.44) | GNPATNMT2NMT1SIRT5FURIN | |
| SCHEMBL13402935 | 0.83 | NMT2 (0.43) | GNPATNMT2NMT1SIRT5FOLH1 | |
| SCHEMBL13402928 | 0.82 | TLR2 (0.48) | NMT2NMT1SIRT5FURINTLR2 | |
| SCHEMBL28497207 | 0.82 | FOLH1 (0.54) | GNPATNMT2NMT1FOLH1SIRT6 | |
| SCHEMBL29514694 | 0.81 | FURIN (0.49) | GNPATSIRT5FURIN | |
| SCHEMBL13402921 | 0.81 | TLR2 (0.48) | NMT2NMT1SIRT5FURINTLR2 | |
| SCHEMBL10168670 | 0.80 | NMT2 (0.44) | NMT2NMT1SIRT5TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210299210-A2 | HETEROTANDEM BICYCLIC PEPTIDE COMPLEXES | BICYCLETX LIMITED (GB) | 2021-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299210-A2 | HETEROTANDEM BICYCLIC PEPTIDE COMPLEXES | TIMCC, TAP1, CD81 | GNPAT 4476/4885NMT2 264/4885NMT1 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.